Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15

References

• Bayo J, Tran TA, Wang L, Pena-Llopis S, Das AK, Martinez ED. Jumonji inhibitors overcome radioresistance in cancer through changes in H3K4 methylation at double-strand breaks. Cell Rep. 2018;25(4):1040–50 e5. doi:10.1016/j.celrep.2018.09.081.
   PubMed Web of Science ®Google Scholar
• D’Oto A, Tian QW, Davidoff AM, Yang J. Histone demethylases and their roles in cancer epigenetics. J of Med Oncol and Ther. 2016;1(2):34–40.
   PubMedGoogle Scholar
• Franci G, Ciotta A, Altucci L. The Jumonji family: past, present and future of histone demethylases in cancer. Biomol Concepts. 2014;5(3):209–224. doi:10.1515/bmc-2014-0010.
   PubMedGoogle Scholar
• Khoury-Haddad H, Nadar-Ponniah PT, Awwad S, Ayoub N. The emerging role of lysine demethylases in DNA damage response: dissecting the recruitment mode of KDM4D/JMJD2D to DNA damage sites. Cell Cycle. 2015;14(7):950–958. doi:10.1080/15384101.2015.1014147.
   PubMed Web of Science ®Google Scholar
• Park SY, Park JW, Chun YS. Jumonji histone demethylases as emerging therapeutic targets. Pharmacol Res. 2016;105:146–151. doi:10.1016/j.phrs.2016.01.026.
   PubMed Web of Science ®Google Scholar
• Hojfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov. 2013;12(12):917–930. doi:10.1038/nrd4154.
   PubMed Web of Science ®Google Scholar
• Rotili D, Mai A. Targeting histone demethylases: a new avenue for the fight against cancer. Genes Cancer. 2011;2(6):663–679. doi:10.1177/1947601911417976.
   PubMedGoogle Scholar
• Dalvi MP, Wang L, Zhong R, Kollipara RK, Park H, Bayo J, Yenerall P, Zhou Y, Timmons BC, Rodriguez-Canales J, et al. Taxane-platin-resistant lung cancers co-develop hypersensitivity to Jumonjic demethylase inhibitors. Cell Rep. 2017;19(8):1669–1684. doi:10.1016/j.celrep.2017.04.077.
   PubMed Web of Science ®Google Scholar
• Kuo KT, Huang WC, Bamodu OA, Lee WH, Wang CH, Hsiao M, Wang LS, Yeh CT. Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor. Clin Epigenet. 2018;10(1):107. doi:10.1186/s13148-018-0533-9.
   PubMedGoogle Scholar
• Li S, Jiang L, He Q, Wei W, Wang Y, Zhang X, Liu J, Chen K, Chen J, Xie D. The prognostic significance of JMJD3 in primary sarcomatoid carcinoma of the lung, a rare subtype of lung cancer. Onco Targets Ther. 2019;12:9385–9393. doi:10.2147/OTT.S225596.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, et al. The prognostic impact of Jumonji domain-containing 2B in patients with resected lung adenocarcinoma. Anticancer Res. 2016;36(9):4841–4846. doi:10.21873/anticanres.11046.
   PubMed Web of Science ®Google Scholar
• Duan L, Perez RE, Chastain PD 2nd, Mathew MT, Bijukumar DR, Maki CG. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019;38(28):5643–5657. doi:10.1038/s41388-019-0814-6.
   PubMed Web of Science ®Google Scholar
• Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL, Yang ZQ. Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res. 2012;4(3):247–256.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69–80. doi:10.1016/j.cell.2010.02.027.
   PubMed Web of Science ®Google Scholar
• Vinogradova M, Gehling VS, Gustafson A, Arora S, Tindell CA, Wilson C, Williamson KE, Guler GD, Gangurde P, Manieri W, et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat Chem Biol. 2016;12(7):531–538. doi:10.1038/nchembio.2085.
   PubMed Web of Science ®Google Scholar
• He C, Sun J, Liu C, Jiang Y, Hao Y. Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin. Clin Epigenet. 2019;11(1):8. doi:10.1186/s13148-018-0605-x.
   PubMedGoogle Scholar
• Zhang B, Long Q, Wu S, Xu Q, Song S, Han L, Qian M, Ren X, Liu H, Jiang J, et al. KDM4 orchestrates epigenomic remodeling of senescent cells and potentiates the senescence-associated secretory phenotype. Nat Aging. 2021;1(5):454–472. doi:10.1038/s43587-021-00063-1.
   PubMedGoogle Scholar
• Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, Ruiz J, Bruick R, Pena-Llopis S, Xu J, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun. 2013;4(1):2035. doi:10.1038/ncomms3035.
   PubMedGoogle Scholar
• Burgess JT, Rose M, Boucher D, Plowman J, Molloy C, Fisher M, O’Leary C, Richard DJ, O’Byrne KJ, Bolderson E. The therapeutic potential of DNA damage repair pathways and genomic stability in lung cancer. Front Oncol. 2020;10:1256. doi:10.3389/fonc.2020.01256.
   PubMed Web of Science ®Google Scholar
• Chen P, Li J, Chen YC, Qian H, Chen YJ, Su JY, Wu M, Lan T. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells. Cellular Oncol. 2016;39(6):511–522. doi:10.1007/s13402-016-0291-7.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. doi:10.1038/onc.2011.384.
   PubMed Web of Science ®Google Scholar
• Canovas B, Igea A, Sartori AA, Gomis RR, Paull TT, Isoda M, Perez-Montoyo H, Serra V, Gonzalez-Suarez E, Stracker TH, et al. Targeting p38alpha increases DNA damage, chromosome instability, and the anti-tumoral response to taxanes in breast cancer cells. Cancer Cell. 2018;33(6):1094–110 e8. doi:10.1016/j.ccell.2018.04.010.
   PubMed Web of Science ®Google Scholar
• Emanuele MJ, Ciccia A, Elia AE, Elledge SJ. Proliferating cell nuclear antigen (PCNA)-associated KIAA0101/PAF15 protein is a cell cycle-regulated anaphase-promoting complex/cyclosome substrate. Proceedings of the National Academy of Sciences of the United States of America; 2011; 108:9845–9850.
   Google Scholar
• Lafranchi L, de Boer HR, de Vries EG, Ong SE, Sartori AA, van Vugt MA. APC/C(Cdh1) controls CtIP stability during the cell cycle and in response to DNA damage. EMBO J. 2014;33(23):2860–2879. doi:10.15252/embj.201489017.
   PubMed Web of Science ®Google Scholar
• Pfleger CM, Lee E, Kirschner MW. Substrate recognition by the Cdc20 and Cdh1 components of the anaphase-promoting complex. Genes Dev. 2001;15(18):2396–2407. doi:10.1101/gad.918201.
   PubMed Web of Science ®Google Scholar
• Price PM, Yu F, Kaldis P, Aleem E, Nowak G, Safirstein RL, Megyesi J. Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J of the Am Soc of Nephrol: JASN. 2006;17(9):2434–2442. doi:10.1681/ASN.2006020162.
   PubMed Web of Science ®Google Scholar
• Lukas C, Sorensen CS, Kramer E, Santoni-Rugiu E, Lindeneg C, Peters JM, Bartek J, Lukas J. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature. 1999;401(6755):815–818. doi:10.1038/44611.
   PubMed Web of Science ®Google Scholar
• Oakes V, Wang W, Harrington B, Lee WJ, Beamish H, Chia KM, Pinder A, Goto H, Inagaki M, Pavey S, et al. Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle. Cell Cycle. 2014;13(20):3302–3311. doi:10.4161/15384101.2014.949111.
   PubMed Web of Science ®Google Scholar
• Sorensen CS, Lukas C, Kramer ER, Peters JM, Bartek J, Lukas J. A conserved cyclin-binding domain determines functional interplay between anaphase-promoting complex-Cdh1 and cyclin A-Cdk2 during cell cycle progression. Mol Cell Biol. 2001;21(11):3692–3703. doi:10.1128/MCB.21.11.3692-3703.2001.
   PubMed Web of Science ®Google Scholar
• Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bartek J, Baer R, Lukas J, Jackson SP. Human CtIP promotes DNA end resection. Nature. 2007;450(7169):509–514. doi:10.1038/nature06337.
   PubMed Web of Science ®Google Scholar
• Povlsen LK, Beli P, Wagner SA, Poulsen SL, Sylvestersen KB, Poulsen JW, Nielsen ML, Bekker-Jensen S, Mailand N, Choudhary C. Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol. 2012;14(10):1089–1098. doi:10.1038/ncb2579.
   PubMed Web of Science ®Google Scholar